• AZD3514: Practical Guidance for AR Downregulation Research

  2026-04-10

  AZD3514 is a potent androgen receptor downregulator suited for advanced prostate cancer research, particularly studies targeting AR signaling and antiandrogen therapy mechanisms. It is not intended for applications lacking AR pathway involvement or outside the context of defined prostate cancer models.

• AZD2461: Next-Generation PARP Inhibitor for Advanced Brea...

  2026-04-10

  Explore the unique advantages of AZD2461, a novel PARP inhibitor, in breast cancer research. This article delves into its molecular action, resistance-bypassing properties, and innovative experimental applications for DNA repair pathway modulation.

• Azithromycin: Macrolide Antibiotic Mechanisms & Research ...

  2026-04-09

  Azithromycin is a 15-membered macrolide antibiotic widely employed as a bacterial protein synthesis inhibitor in infection research. Its efficacy and specificity for the 50S ribosomal subunit underpin its utility for resistance screening and trypanosomosis models. APExBIO’s formulation offers benchmark reproducibility and meets stringent analytical and storage criteria.

• Azathramycin A: Macrolide Antibiotic for Tuberculosis Res...

  2026-04-08

  Azathramycin A stands out as a macrolide antibiotic and ribosome inhibitor of Mycobacterium tuberculosis, enabling precise protein synthesis inhibition studies and antibiotic resistance modeling. Its unique properties as an azithromycin degradation product empower researchers to dissect ribosomal mechanisms and optimize tuberculosis infection models with reproducible, high-specificity results.

• Lypressin Acetate: Advanced Insights into Vasopressin Rec...

  2026-04-08

  Explore the multifaceted science of Lypressin acetate, a potent vasopressin analog and G protein-coupled receptor agonist, as both a benchmark in antidiuretic hormone analog research and a promising SARS-CoV-2 RdRp inhibitor. This article delivers unique mechanistic depth, translational perspectives, and the latest breakthroughs beyond standard applications.

• Azathramycin A: Macrolide Ribosome Inhibitor for Tubercul...

  2026-04-07

  Azathramycin A is a macrolide antibiotic and ribosome inhibitor of Mycobacterium tuberculosis, providing a well-characterized pathway for bacterial protein synthesis inhibition. As a verified impurity and degradation product of Azithromycin, Azathramycin A enables precise, reproducible studies of antibiotic mechanisms and resistance in tuberculosis research.

• AZD0156: Selective ATM Kinase Inhibitor for Cancer Research

  2026-04-07

  AZD0156 is a potent, highly selective ATM kinase inhibitor for cancer research, enabling precise dissection of the DNA damage response pathway. This small molecule from APExBIO offers sub-nanomolar potency and exceptional selectivity, facilitating studies in genomic stability and checkpoint control. Its unique solubility and storage profile support robust preclinical and translational research workflows.

• AZD2461: Redefining PARP Inhibition and Resistance in Bre...

  2026-04-06

  Explore the multifaceted role of AZD2461, a novel PARP inhibitor, in breast cancer research—highlighting its unique mechanisms in overcoming Pgp-mediated resistance, inducing G2-phase cell cycle arrest, and extending relapse-free survival. This in-depth analysis uncovers advanced strategies for DNA repair pathway modulation and resistance studies.

• AZD2461: Novel PARP Inhibitor for Breast Cancer Research

  2026-04-06

  AZD2461 is a next-generation poly (ADP-ribose) polymerase inhibitor with high specificity for PARP-1, demonstrating robust cytotoxicity in breast cancer cell lines and overcoming P-glycoprotein-mediated drug resistance. This dossier details its molecular mechanism, experimental benchmarks, and integration into advanced DNA repair and relapse prevention research workflows.

• Azathramycin A: Macrolide Ribosome Inhibitor for Tubercul...

  2026-04-05

  Azathramycin A is a macrolide antibiotic and ribosome inhibitor of Mycobacterium tuberculosis, providing a validated model for bacterial protein synthesis inhibition in tuberculosis research. As a major impurity of azithromycin, it is critical for antibiotic resistance and degradation pathway studies.

• Azithromycin (SKU B1398): Reliable Solutions for Bacteria...

  2026-04-04

  This article delivers a scenario-driven, evidence-based exploration of Azithromycin (SKU B1398) as a macrolide antibiotic for cell-based assays, resistance screening, and animal infection models. Researchers will find practical guidance grounded in quantitative data, comparative insights, and validated protocols, with a focus on experimental reproducibility and workflow integrity.

• Azathramycin A: Macrolide Ribosome Inhibitor for Mycobact...

  2026-04-03

  Azathramycin A is a macrolide antibiotic and potent ribosome inhibitor of Mycobacterium tuberculosis. It serves as a critical antibacterial agent in tuberculosis research, particularly for modeling infection and resistance pathways. As a characterized impurity of Azithromycin, it is a robust tool for mechanistic and translational studies.

• Azithromycin: Macrolide Antibiotic Workflows in Infection...

  2026-04-03

  Azithromycin stands out as a robust macrolide antibiotic, enabling advanced bacterial infection research and trypanosomosis modeling through precise inhibition of the 50S ribosomal subunit. This guide delivers scenario-driven workflows, quantifiable resistance screening, and expert troubleshooting, all powered by APExBIO’s high-purity Azithromycin. Discover how to maximize assay reliability, interpret complex resistance data, and accelerate translational discoveries in antimicrobial research.

• ATM Kinase Inhibition in Cancer: Mechanistic Insights and...

  2026-04-02

  Explore how selective ATM kinase inhibition—exemplified by AZD0156—redefines DNA damage response, metabolic adaptation, and checkpoint modulation in cancer research. This thought-leadership article synthesizes mechanistic rationale, experimental validation, and translational guidance to empower researchers pursuing next-generation precision therapies.

• Cinoxacin: Quinolone Antibiotic Benchmarks for Gram-Negat...

  2026-04-02

  Cinoxacin is a synthetic quinolone antibiotic with high activity against Gram-negative bacteria, especially Escherichia coli, making it a key agent in urinary tract infection research. Its precise DNA replication inhibition mechanism and well-characterized MIC parameters allow reproducible workflows in antimicrobial and resistance studies. This article delivers atomic, referenced facts on Cinoxacin's mechanism, assay conditions, and practical limitations for robust laboratory use.

15213 records 1/1015 page Next 12345 下5页 Last page